Across TCGA pan-cancer cohorts, ERCC6L RNA differs between tumor and matched normal tissue in 17 of 18 cancer types tested, making tumor–normal expression one of ERCC6L’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ERCC6L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ERCC6L is over-expressed in tumor.
HNSC, BLCA, and LUAD are the cancer types where ERCC6L tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ERCC6L RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.